Loading...

Discounted Cash Flow (DCF) Analysis Unlevered


Ampio Pharmaceuticals Inc.

Ampio Pharmaceuticals Inc. (AMPE)

Healthcare

Operating Data

Year
A/P
2013
Actual
2014
Actual
2015
Actual
2016
Actual
2017
Actual
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
Revenue 0.05----------
Revenue (%)
EBITDA -23.88----------
EBITDA (%)
EBIT -24.02----------
EBIT (%)
Depreciation 0.14----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2013
Actual
2014
Actual
2015
Actual
2016
Actual
2017
Actual
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
Total Cash 26.35----------
Total Cash (%)
Account Receivables -----------
Account Receivables (%)
Inventories -----------
Inventories (%)
Accounts Payable 1.90----------
Accounts Payable (%)
Capital Expenditure -1.31----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 0.44
Diluted Shares Outstanding 73.36
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 0.05
Risk-Free Rate
Market Risk Premium
Cost of Equity 13.90
Total Debt -
Total Equity 32.28
Total Capital 32.28
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash

Year
A/P
2013
Actual
2014
Actual
2015
Actual
2016
Actual
2017
Actual
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
Revenue 0.05----------
EBITDA -23.88----------
EBIT -24.02----------
Tax Rate 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EBIAT -24.02----------
Depreciation 0.14----------
Accounts Receivable -----------
Inventories -----------
Accounts Payable -----------
Capital Expenditure -----------
UFCF -23.88----------
WACC
PV UFCF -----
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 13.90
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -
Equity Value -
Shares Outstanding 73.36
Equity Value Per Share -